HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $14.89, but opened at $14.50. HUTCHMED shares last traded at $14.35, with a volume of 8,301 shares.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday, March 21st.
Read Our Latest Analysis on HCM
HUTCHMED Trading Up 0.1 %
The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $14.81 and a 200-day moving average of $15.97.
Institutional Investors Weigh In On HUTCHMED
A number of large investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio lifted its stake in HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after acquiring an additional 899 shares during the period. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after purchasing an additional 1,647 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after buying an additional 1,799 shares during the period. Barclays PLC lifted its holdings in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the period. Finally, State Street Corp boosted its position in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock valued at $6,826,000 after acquiring an additional 3,078 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
